Invivyd Inc. (IVVD) - Total Assets
Based on the latest financial reports, Invivyd Inc. (IVVD) holds total assets worth $276.88 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IVVD net asset value for net asset value and shareholders' equity analysis.
Invivyd Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s total assets have evolved over time, based on quarterly financial data.
Invivyd Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Invivyd Inc.'s total assets of $276.88 Million consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.9% |
| Accounts Receivable | $13.92 Million | 5.0% |
| Inventory | $25.50 Million | 9.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IVVD market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Invivyd Inc.'s current assets represent 89.4% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 81.9% of total assets in 2025, down from 98.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 9.2% of total assets.
Invivyd Inc. Competitors by Total Assets
Key competitors of Invivyd Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Invivyd Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.24 | 1.62 | 3.31 |
| Quick Ratio | 6.50 | 1.21 | 3.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $213.30 Million | $38.70 Million | $66.20 Million |
Invivyd Inc. - Advanced Valuation Insights
This section examines the relationship between Invivyd Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.47 |
| Latest Market Cap to Assets Ratio | 1.55 |
| Asset Growth Rate (YoY) | 113.8% |
| Total Assets | $276.88 Million |
| Market Capitalization | $428.62 Million USD |
Valuation Analysis
Above Book Valuation: The market values Invivyd Inc.'s assets above their book value (1.55x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Invivyd Inc.'s assets grew by 113.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Invivyd Inc. (2020–2025)
The table below shows the annual total assets of Invivyd Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $276.88 Million | +113.78% |
| 2024-12-31 | $129.51 Million | -43.49% |
| 2023-12-31 | $229.18 Million | -40.19% |
| 2022-12-31 | $383.17 Million | -38.21% |
| 2021-12-31 | $620.09 Million | +428.27% |
| 2020-12-31 | $117.38 Million | -- |
About Invivyd Inc.
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which i… Read more